

**Biotechnology Fund**  
**SCHEDULE OF INVESTMENTS (Unaudited)**

December 31, 2025

	Shares	Value
<b>COMMON STOCKS<sup>†</sup> - 99.6%</b>		
<b>Biotechnology - 70.6%</b>		
Amgen, Inc.	16,516	\$ 5,405,852
Gilead Sciences, Inc.	39,844	4,890,453
Vertex Pharmaceuticals, Inc.*	10,599	4,805,163
Regeneron Pharmaceuticals, Inc.	5,152	3,976,674
Alnylam Pharmaceuticals, Inc.*	7,947	3,160,125
Insmed, Inc.*	14,529	2,528,627
Biogen, Inc.*	12,936	2,276,607
BeOne Medicines Ltd. ADR*	7,379	2,241,814
United Therapeutics Corp.*	4,137	2,015,753
Royalty Pharma plc — Class A	51,524	1,990,887
Illumina, Inc.*	14,715	1,930,019
Incyte Corp.*	18,317	1,809,170
Revolution Medicines, Inc.*	21,352	1,700,687
Bridgebio Pharma, Inc.*	21,199	1,621,511
BioMarin Pharmaceutical, Inc.*	26,548	1,577,748
Ionis Pharmaceuticals, Inc.*	19,693	1,557,913
Argenx SE ADR*	1,845	1,551,553
Exelixis, Inc.*	34,986	1,533,436
Moderna, Inc.*	48,915	1,442,503
Avidity Biosciences, Inc.*	19,911	1,436,180
Roivant Sciences Ltd.*	61,011	1,323,939
Halozyne Therapeutics, Inc.*	19,343	1,301,784
Cytokinetics, Inc.*	20,111	1,277,853
Arrowhead Pharmaceuticals, Inc.*	18,776	1,246,539
CRISPR Therapeutics AG*	23,590	1,237,060
BioNTech SE ADR*	12,684	1,207,517
Amicus Therapeutics, Inc.*	78,127	1,112,528
PTC Therapeutics, Inc.*	14,278	1,084,557
Axsome Therapeutics, Inc.*	5,927	1,082,507
TG Therapeutics, Inc.*	29,921	891,945
Legend Biotech Corp. ADR*	39,822	865,730
ADMA Biologics, Inc.*	47,114	859,359
Travere Therapeutics, Inc.*	22,050	842,530
Viking Therapeutics, Inc.*	23,939	842,174
Scholar Rock Holding Corp.*	18,732	825,145
ACADIA Pharmaceuticals, Inc.*	30,598	817,273
Veracyte, Inc.*	19,321	813,414
Arcutis Biotherapeutics, Inc.*	27,126	787,739
Apellis Pharmaceuticals, Inc.*	29,157	732,424
Beam Therapeutics, Inc.*	25,336	702,314
Kymera Therapeutics, Inc.*	8,853	688,852
Liquidia Corp.*	19,725	680,315
Celcuity, Inc.*	6,702	668,457
Sarepta Therapeutics, Inc.*	30,630	659,158
Soleno Therapeutics, Inc.*	14,213	658,062
Nuvalent, Inc. — Class A*	6,277	631,403
Recursion Pharmaceuticals, Inc. — Class A*	149,289	610,592
Summit Therapeutics, Inc.*	33,632	588,224
Krystal Biotech, Inc.*	2,380	586,765
Ultragenyx Pharmaceutical, Inc.*	22,214	510,922
Arcellx, Inc.*	7,434	484,697
Intellia Therapeutics, Inc.*	48,347	434,640
<b>Total Biotechnology</b>		<b>76,509,093</b>
<b>Pharmaceuticals - 21.3%</b>		
AbbVie, Inc.	35,903	8,203,476
AstraZeneca plc ADR	26,373	2,424,470
Viatis, Inc.	140,709	1,751,827
Neurocrine Biosciences, Inc.*	11,298	1,602,395
Jazz Pharmaceuticals plc*	8,580	1,458,600
Alkermes plc*	43,315	1,211,954
Cidara Therapeutics, Inc.*	4,967	1,097,161
Vaxcyte, Inc.*	23,633	1,090,427
Protagonist Therapeutics, Inc.*	11,396	995,327
Madrigal Pharmaceuticals, Inc.*	1,637	953,290
Rhythm Pharmaceuticals, Inc.*	8,285	886,826
Ascendis Pharma A/S ADR*	3,657	779,819
Mirum Pharmaceuticals, Inc.*	8,493	670,862
<b>Total Pharmaceuticals</b>		<b>23,126,434</b>
<b>Healthcare-Products - 6.5%</b>		
Natera, Inc.*	10,785	2,470,736
Exact Sciences Corp.*	18,983	1,927,913
Guardant Health, Inc.*	15,544	1,587,664
Twist Bioscience Corp.*	19,190	608,707
GRAIL, Inc.*	4,486	383,957
<b>Total Healthcare-Products</b>		<b>6,978,977</b>
<b>Healthcare-Services - 1.2%</b>		
Medpace Holdings, Inc.*	2,281	1,281,124
<b>Total Common Stocks</b> (Cost \$53,815,040)		<b>107,895,628</b>
<b>RIGHTS<sup>†</sup> - 0.0%</b>		
<b>Pharmaceuticals - 0.0%</b>		
Novo Nordisk A/S*	17,387	—
Sanofi SA*	8,866	—
<b>Total Pharmaceuticals</b>		<b>—</b>
<b>Total Rights</b> (Cost \$—)		<b>—</b>
	<b>Face</b>	<b>Amount</b>
<b>REPURCHASE AGREEMENTS<sup>††,1</sup> - 0.2%</b>		
BofA Securities, Inc. issued 12/31/25 at 3.81% due 01/02/26	\$ 117,823	117,823

J.P. Morgan Securities LLC  
issued 12/31/25 at 3.82%  
due 01/02/26

	117,823	117,823
<b>Total Repurchase Agreements</b>		
(Cost \$235,646)		235,646
<b>Total Investments - 99.8%</b>		
(Cost \$54,050,686)	\$	108,131,274
<b>Other Assets &amp; Liabilities, net - 0.2%</b>		264,232
<b>Total Net Assets - 100.0%</b>	\$	108,395,506

**Biotechnology Fund**  
**SCHEDULE OF INVESTMENTS (Unaudited)**

December 31, 2025

- 
- \* *Non-income producing security.*
  - † *Value determined based on Level 1 inputs.*
  - †† *Value determined based on Level 2 inputs.*
  - 1 *Repurchase Agreements.*

*ADR — American Depositary Receipt*  
*plc — Public Limited Company*